Welcome to our dedicated page for Dbv Technologies S A news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on Dbv Technologies S A stock.
The DBV Technologies S.A. (DBVT) news page on Stock Titan aggregates company announcements, regulatory disclosures, and clinical development updates for this clinical-stage biopharmaceutical issuer. DBV Technologies focuses on food allergies and other immunologic conditions with significant unmet medical need, using its proprietary Viaskin patch technology and epicutaneous immunotherapy (EPIT) platform.
Investors and followers of DBV Technologies can use this news feed to review company-issued press releases and market announcements. Recent communications from DBV Technologies have covered topics such as progress in its Viaskin Peanut clinical program in peanut-allergic toddlers and children, including the Phase 3 VITESSE trial in children aged 4 to 7 years. The company has reported that VITESSE met its primary endpoint and that safety results were consistent with the existing Viaskin Peanut clinical program, positioning this trial as a key milestone in its development strategy.
In addition to clinical data updates, DBV Technologies news items include information on supplemental safety studies in toddlers, participation in healthcare and investor conferences, and changes in leadership and board composition. The company also releases regulated information related to its Euronext Paris listing, such as monthly disclosures of total shares and voting rights and reports on its liquidity contract.
Regulatory filings summarized in press releases, including U.S. SEC Form 8-K reports, provide insight into financial results, equity financing arrangements, and other corporate events. By following DBV Technologies news, readers can track developments in the Viaskin platform, food allergy programs, and the company’s dual listing on Euronext Paris and the Nasdaq Capital Market.
As of January 31, 2021, the company reported a total of 54,929,187 shares outstanding. This includes 54,883,187 net voting rights, calculated by subtracting shares without voting rights from the total shares. This report adheres to Article 223-16 of the General Regulations of the Autorité des Marchés Financiers.
DBV Technologies released its Half-Year Report on the liquidity contract with ODDO BHF, detailing its assets as of December 31, 2020. The liquidity account held 112,302 shares and €229,086.53, compared to 24,313 shares and €682,454.94 at contract signing in July 2018. During the second half of 2020, 1,180 purchases and 1,136 sales were executed, totaling 517,291 shares bought for €2,005,858.40 and 458,090 shares sold for €1,841,496.60.
DBV Technologies (Ticker: DBVT) announced on January 14, 2020, that it received feedback from the FDA concerning its Viaskin™ Peanut patch for treating peanut allergies in children aged 4-11. Following a Complete Response Letter, the FDA provided guidance on patch modifications and the need for a new human factors study. DBV aims to start prototype selection in Q1 2021 and plans to submit a safety trial protocol in Q2 2021. The company is optimistic about extending its cash runway to the second half of 2022 due to ongoing restructuring efforts.
DBV Technologies has transitioned to a U.S. domestic issuer, effective January 1, 2021, requiring compliance with SEC regulations. The company will file periodic reports in U.S. dollars and continue with IFRS reporting in Europe. A global restructuring process, approved today, will cut over 200 jobs, leaving a team of 90, expected to enhance operational efficiency for the Viaskin Peanut development. DBV anticipates a 40-50% reduction in monthly cash burn by mid-2021, aiming to extend its cash runway into the second half of 2022.
Monthly Update: As of December 31, 2020, the company reported a total of 54,929,187 shares and 54,929,187 voting rights on the NYSE Euronext Paris. The net voting rights total was 54,816,885, accounting for shares without voting rights.
This disclosure adheres to Article 223-16 of the General Regulations of the Autorité des Marchés Financiers, ensuring transparency and compliance in reporting shareholding details.
As of November 30, 2020, the company reported a total of 54,929,187 shares outstanding on the NYSE Euronext Paris. The total number of voting rights associated with these shares is 54,929,187, while the net total of voting rights, accounting for shares without voting rights, stands at 54,815,187. This information complies with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers.
DBV Technologies announced leadership changes with Dr. Hugh Sampson stepping down as Chief Scientific Officer effective December 1, 2020. He will transition to a role as Scientific Adviser to the CEO, remaining involved with the development of the epicutaneous immunotherapy platform. Dr. Sampson, who has been influential in advancing food allergy treatments, believes this change allows him to refocus on his research at Mount Sinai. DBV’s commitment to the Viaskin technology remains strong as they continue clinical trials aimed at food allergies.
Company Update: As of October 31, 2020, the total number of shares for the Company is 54,927,187, with a total number of voting rights amounting to 54,927,187 (gross) and 54,786,929 (net). This data reflects compliance with the Autorité des Marchés Financiers regulations.
Market: NYSE Euronext Paris | ISIN Code: FR 0010417345
DBV Technologies will present new data on its Viaskin™ Peanut treatment at the ACAAI Annual Scientific Meeting from Nov. 13-15, 2020. Key highlights include four accepted abstracts, with one oral presentation and three poster presentations, detailing the treatment's patient experience, patch adhesion, and prediction of desensitization to peanuts. The event will also feature a symposium on managing food allergies during the COVID-19 pandemic. DBV's ongoing commitment to innovative treatments aims to ease the burden of peanut allergies for patients and families.
DBV Technologies announced its participation in several upcoming virtual investor conferences. CEO Daniel Tassé will host fireside chats at the following:
- Credit Suisse Healthcare Conference: November 11, 2020, at 12:30 PM ET
- Stifel Healthcare Conference: November 16, 2020, at 8:00 AM ET
- Evercore HealthconX: December 1, 2020, at 12:35 PM ET
Webcasts will be available on the company’s website, with replays posted afterward. DBV focuses on developing Viaskin™, an innovative immunotherapy platform for food allergies.
FAQ
What is the current stock price of Dbv Technologies S A (DBVT)?
What is the market cap of Dbv Technologies S A (DBVT)?
